本文源自：金融界 6月12日，北部湾港今日收盘8.66元，下跌1.37%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到19.67倍，总市值201.44亿元。 作者：行情君 从行业市盈率排名来看，公司所处的航运港口行业市盈率平均14.02倍，行业中值14.63倍，北部湾港排 名第25位。 最新一期业绩显示，2025年一季报，公司实现营业收入16.43亿元，同比6.73%；净利润1.96亿元，同 比-49.87%，销售毛利率29.74%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)25北部湾港19.6716.521.14201.44亿行业平均 14.2616.691.21292.85亿行业中值14.6315.031.22131.97亿1国航远洋-736.86283.554.7864.26亿2凤凰航 运-62.46-58.6210.6248.48亿3*ST锦港-0.28-0.28-13.1018.22亿4中远海控4.565.021.012465.96亿5招商南油 8.516.801.18130.61亿6上港集团8.848.970.981341.01亿7招商轮船10.899.801.235 ...

北矿科技（600980）发布异动公告，2025年6月11日，公司所处的"C35专用设备制造业"行业静态市盈 率为29.57，滚动市盈率为28.92；公司静态市盈率为40.69，滚动市盈率为40.27，公司静态市盈率及滚动 市盈率均高于行业市盈率水平。经公司自查，公司及子公司目前生产经营正常，内外部经营环境未发生 重大变化，不存在影响公司股票交易价格异常波动的重大事宜，不存在应披露而未披露的重大事项。 ...

6月10日，安杰思今日收盘64.97元，上涨1.83%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到17.72倍，创12天以来新低，总市值52.61亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.00倍，行业中值37.03倍，安杰思排名 第41位。 截至2025年一季报，共有11家机构持仓安杰思，其中基金6家、其他5家，合计持股数1773.25万股，持 股市值12.60亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。报告期内，公司取得重要政府荣誉7项，获 得"浙江省级企业技术中心"、"浙江省生物医药高成长型企业"、"浙江省首批两新重大科技成果"、"杭 州市绿色工厂"、"杭州市优质产品（止血夹）2023年杭州市总部企业"等荣誉。 最新一期业绩显示，2025年一季报，公司实现营业收入1.29亿元，同比15.27%；净利润5624.83万元， 同比6.57%，销售毛利率70.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)41安杰思17.7217.93 ...

Company Overview - Nuwei CNC specializes in the research, production, and sales of mid-to-high-end CNC machine tools, including large machining centers, vertical CNC machines, and horizontal CNC machines [2] - The company has received multiple accolades, including the CNAS certification for its testing center, recognition as a five-star cloud enterprise in Jiangsu Province, and various quality awards [2] Financial Performance - For Q1 2025, the company reported a revenue of 569 million yuan, representing a year-on-year increase of 3.80% [2] - The net profit for the same period was approximately 61.36 million yuan, showing a year-on-year decrease of 11.78% [2] - The sales gross margin stood at 21.11% [2] Market Position - As of June 10, Nuwei CNC's stock closed at 19.28 yuan, down 1.93%, with a rolling PE ratio of 19.87 times [1] - The company's total market capitalization is approximately 6.298 billion yuan [1] - In comparison to the general equipment industry, which has an average PE ratio of 77.89 times and a median of 38.60 times, Nuwei CNC ranks 65th in terms of PE ratio [1][3] Shareholder Information - As of March 31, 2025, Nuwei CNC had 11,793 shareholders, a decrease of 431 from the previous count, with an average holding value of 352,800 yuan per shareholder [1] - The average number of shares held per shareholder is 27,600 [1]

券商股对A股市场活跃度的敏感程度呈几何型增长，这是其估值的独特之处。市场活跃度不仅体现在成 交量上，还包括投资者的参与热情、市场情绪等多个方面。当市场活跃度较高时，投资者信心增强，资 金大量涌入股市，推动股价上涨，券商股作为市场的风向标，往往会率先受益。反之，当市场陷入低 迷，投资者观望情绪浓厚，交易冷清，券商股的业绩和估值也会受到较大冲击。这种对市场活跃度的高 度敏感性，使得券商股的估值波动较大，不能单纯依靠市盈率来衡量。 全面考量券商股的估值，需要综合考虑市盈率和股市成交量等多方面因素。投资者在分析券商股时，不 仅要关注公司的财务数据和盈利能力，还要密切关注市场的整体走势和交易活跃度。例如，在市场行情 向好、成交量持续放大的情况下，即使券商股的市盈率相对较高，也可能因为其未来盈利增长的预期而 具备投资价值；相反，在市场低迷、成交量萎缩时，即使市盈率较低，也不能盲目认为券商股被低估， 因为其业绩可能面临较大压力。 从投资策略的角度来看，投资者应根据市场的不同阶段和券商股的具体情况，灵活调整投资思路。在市 场活跃期，可以适当加大对券商股的投资比例，分享市场上涨带来的收益；而在市场调整期，则要保持 谨慎，关注券 ...

合富(中国)医疗科技股份有限公司的主营业务是从事以体外诊断相关的医疗设备及其耗材为主的国际贸 易、售后服务，贸易代理，从事医院信息管理系统的咨询服务以及相关配套服务。公司的主要产品是体 外诊断产品集约化业务、医疗产品流通。 最新一期业绩显示，2025年一季报，公司实现营业收入1.76亿元，同比-26.35%；净利润-6001192.11 元，同比-184.13%，销售毛利率16.71%。 6月10日，合富中国今日收盘6.85元，下跌1.01%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到188.94倍，总市值27.27亿元。 从行业市盈率排名来看，公司所处的医药商业行业市盈率平均45.24倍，行业中值28.56倍，合富中国排 名第26位。 截至2025年一季报，共有5家机构持仓合富中国，其中其他4家、QFII1家，合计持股数22456.10万股， 持股市值15.29亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)26合富中国188.9498.912.3427.27亿行业平均 45.2434.022.09112.61亿行业中值28.5624.381.3861.85亿1漱玉平民-29 ...

Group 1 - The core viewpoint of the article highlights that Aier Eye Hospital's stock closed at 12.47 yuan, down 1.42%, with a rolling PE ratio of 31.38 times and a total market capitalization of 116.288 billion yuan [1] - The average PE ratio for the medical services industry is 41.83 times, with a median of 45.41 times, placing Aier Eye Hospital at the 22nd position in the industry ranking [1] - As of March 31, 2025, Aier Eye Hospital had 347,329 shareholders, a decrease of 31,805 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Aier Eye Hospital's main business includes diagnosis and surgical services for various eye diseases, with key products being refractive projects, cataract projects, anterior segment projects, posterior segment projects, and vision services [1] - In the latest quarterly report for Q1 2025, the company achieved an operating revenue of 6.026 billion yuan, a year-on-year increase of 15.97%, and a net profit of 1.050 billion yuan, up 16.71%, with a gross profit margin of 48.02% [1]

最新一期业绩显示，2025年一季报，公司实现营业收入5.50亿元，同比28.80%；净利润1.03亿元，同比 67.04%，销售毛利率69.64%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)80大博医疗39.6244.214.94157.74亿行业平均 51.0048.824.68108.70亿行业中值37.0337.302.5049.80亿1天益医疗-1801.27-3085.371.9222.95亿2澳华内 镜-688.49345.315.5272.56亿3诺唯赞-425.24-502.942.3391.00亿4爱朋医疗-416.91316.735.0234.21亿5博晖 创新-341.86542.483.6550.16亿6奥精医疗-150.60-220.731.9927.95亿7硕世生物-144.86-2116.821.3042.37亿 8睿昂基因-104.65-85.921.4813.55亿9康泰医学-87.91-74.273.1457.86亿10中红医疗-73.24-58.410.9350.90亿 11热景生物-66.56-76.694.91146.48亿 来源：金融界 6月10日，大 ...

6月9日，瑞迈特今日收盘84.6元，下跌1.12%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到42.73倍，总市值75.80亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.64倍，行业中值37.05倍，瑞迈特排名 第85位。 截至2025年一季报，共有14家机构持仓瑞迈特，其中基金6家、其他5家、券商2家、社保1家，合计持股 数2691.88万股，持股市值21.72亿元。 北京瑞迈特医疗科技股份有限公司的主营业务是呼吸健康领域医疗设备与耗材产品制造。公司的主要产 品是单水平睡眠呼吸机、双水平睡眠呼吸机、双水平肺病呼吸机、P5系列单水平睡眠呼吸机、全脸面 罩、鼻面罩、鼻垫式面罩、睡眠呼吸初筛仪、多导睡眠呼吸监测仪、HT系列高流量湿化氧疗仪、H-80 系列高流量湿化氧疗仪、R系列双水平无创呼吸机。公司拥有633项国内专利，其中国内发明专利107 项、国内实用新型专利390项、国内外观设计专利136项；国际专利202项，其中包括美国专利39项、欧 洲专利30项、欧盟外观专利26项、英国专利46项、土耳其专利12项、日本专利21项、澳大利亚专利6 项、印度专利18项、沙特阿拉伯专 ...

Group 1 - The core viewpoint of the news is that Chao Yan Co., Ltd. has a high rolling price-to-earnings (PE) ratio of 70.66, significantly above the industry average of 50.64, indicating a premium valuation in the medical device sector [1][2] - As of June 9, the company's stock closed at 26.11 yuan, with a market capitalization of 11.184 billion yuan, reflecting a 1.28% increase [1] - The company has experienced a net outflow of main funds amounting to 245.27 million yuan on June 9, with a total outflow of 2,328.49 million yuan over the past five days [1] Group 2 - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with key products including industrial ultrasound, medical ultrasound, and X-ray equipment [1] - The company has established a strong market presence and customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong Province brand product [1] - In 2022, the company received a second-class award for national defense technology invention from the Ministry of Industry and Information Technology for its project on "New Technology for High-Precision Non-Destructive Testing of Complex Large Components and Its Major Applications" [1] Group 3 - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 98.4324 million yuan, representing a year-on-year increase of 28.69%, and a net profit of 39.3220 million yuan, up 47.70% year-on-year, with a gross profit margin of 73.83% [1]